Rezdiffra (Resmetirom) and Prednisone Interaction: What Women with MASH Need to Know

Can You Take Rezdiffra (Resmetirom) with Prednisone?

You can take resmetirom and prednisone at the same time, but the combination requires active monitoring, not passive reassurance. The FDA prescribing information for resmetirom does not list prednisone as a contraindicated co-medication, and no pharmacokinetic data from controlled studies shows one drug meaningfully altering the blood levels of the other. What the interaction produces instead is a pharmacodynamic collision: prednisone does the opposite of what resmetirom is trying to accomplish in your liver and metabolism.

Resmetirom selectively activates thyroid hormone receptor-beta in the liver, reducing hepatic fat, lowering LDL cholesterol, and improving insulin sensitivity. Prednisone, a synthetic glucocorticoid, promotes hepatic glucose output, stimulates fat redistribution to visceral depots, and worsens insulin resistance. If you have MASH, these two drugs are working against each other at the disease level, even if they are not blocking each other at the enzyme level.

Who Gets Both Drugs?

Women with MASH often carry a cluster of other diagnoses. MASH affects roughly 6.5% of the US adult population, and women with autoimmune conditions such as rheumatoid arthritis, lupus, inflammatory bowel disease, or asthma are frequently prescribed prednisone for flares. Because autoimmune disease disproportionately affects women at a rate of roughly 4:1 compared to men, this combination will appear more often in female patients than in male patients.

The MASH-Glucocorticoid Conflict

Glucocorticoid-associated fatty liver is a well-documented phenomenon. Chronic corticosteroid use increases hepatic triglyceride accumulation by suppressing fatty acid oxidation and promoting lipogenesis through SREBP-1c, the same pathway that MASH pathology depends on. Prescribing prednisone to a woman already managing MASH is metabolically counterproductive, and adding resmetirom does not fully neutralize that burden.

How Resmetirom Works (and Why Prednisone Fights It)

Resmetirom is a first-in-class, liver-directed THR-β agonist approved at 80 mg or 100 mg once daily based on body weight. In the MAESTRO-NASH trial (n=966), resmetirom met both co-primary endpoints: MASH resolution without worsening fibrosis in 25.9% (80 mg) and 29.9% (100 mg) of participants versus 9.7% placebo, and fibrosis improvement of at least one stage in 24.2% (80 mg) and 25.9% (100 mg) versus 14.2% placebo.

THR-β Selectivity and Hepatic Lipid Metabolism

THR-β is the dominant thyroid receptor isoform in the liver. When resmetirom binds it, it mimics thyroid hormone's metabolic effects on hepatocytes without activating the cardiac THR-α receptor. This results in increased mitochondrial fatty acid oxidation, reduced de novo lipogenesis, and lower hepatic triglyceride content.

How Prednisone Undercuts This

Prednisone is a prodrug converted to prednisolone by 11-beta-hydroxysteroid dehydrogenase (11β-HSD1). Prednisolone binds the glucocorticoid receptor and drives:

• Increased hepatic glucose output via gluconeogenesis
• Increased visceral fat deposition through lipoprotein lipase suppression in subcutaneous fat
• Elevated free fatty acid flux into the liver, refueling hepatic triglyceride synthesis
• Insulin resistance at the hepatic and peripheral level

Each of those effects directly opposes resmetirom's therapeutic goals. Glucocorticoid receptor activation promotes SREBP-1c expression, the transcription factor that drives the de novo lipogenesis resmetirom is designed to reduce.

CYP Enzymes: Is There a Pharmacokinetic Interaction?

Resmetirom is metabolized primarily by CYP2C8 and CYP3A4. Prednisone and prednisolone are substrates of CYP3A4 but are not clinically significant inhibitors or inducers of CYP3A4 at standard doses. The FDA resmetirom label does not flag a PK interaction with corticosteroids, and no dedicated drug interaction study between resmetirom and prednisone has been published in the peer-reviewed literature as of mid-2025. That evidence gap matters. It means absence of a documented PK interaction, not proof of safety.

Resmetirom is also a substrate of the OATP1B1 and OATP1B3 hepatic uptake transporters. Prednisone does not significantly inhibit these transporters, so hepatic uptake of resmetirom is unlikely to be impaired.

Glucose and Metabolic Risks: The Most Immediate Concern

For women with MASH, the metabolic overlap between prednisone and the underlying disease is the most clinically pressing risk. MASH is tightly linked to insulin resistance and type 2 diabetes. Up to 75% of patients with type 2 diabetes have evidence of hepatic steatosis, and MASH appears on the spectrum of that metabolic dysfunction.

What Prednisone Does to Blood Sugar

Even short courses of prednisone raise postprandial glucose. At doses of 20 mg/day or higher, fasting hyperglycemia is common, and steroid-induced diabetes mellitus (SIDM) occurs in roughly 20-50% of patients without pre-existing diabetes who are placed on chronic glucocorticoids. In women with existing insulin resistance, including those with PCOS or metabolic syndrome driving their MASH, the risk of SIDM is higher.

Monitoring Protocol

If you are starting or continuing prednisone while on resmetirom, your clinician should:

1. Obtain a fasting glucose and HbA1c at baseline
2. Check postprandial glucose (2-hour post-meal) within 2-4 weeks of any prednisone dose increase, because steroid-induced hyperglycemia typically peaks postprandially
3. Reassess HbA1c every 3 months while both drugs are active
4. Adjust antidiabetic therapy proactively if fasting glucose exceeds 126 mg/dL or HbA1c rises above 6.5%

This monitoring framework addresses a real clinical gap: most published MASH management guidelines focus on metabolic syndrome broadly but do not specify how to monitor glucose when a MASH-targeted therapy is co-prescribed with a glucocorticoid. The MAESTRO-NASH trial excluded patients on systemic corticosteroids, which means no trial data informs this exact scenario.

Bone Health: A Particular Risk for Women

Glucocorticoid-induced osteoporosis (GIOP) is the most common form of secondary osteoporosis. Prednisone at doses of 7.5 mg/day or more for 3 months or longer causes clinically meaningful bone loss, predominantly at the lumbar spine and hip. Women lose bone faster than men on equivalent glucocorticoid doses because estrogen already partly protects bone remodeling, and any reduction in estrogen status amplifies corticosteroid-mediated osteoblast suppression.

Life-Stage Considerations for Bone

Reproductive years (roughly ages 18-45): Bone loss from prednisone is real but partially offset by endogenous estrogen. You still need monitoring, particularly if you have irregular menstrual cycles or hypothalamic amenorrhea from MASH-related metabolic dysfunction.

Perimenopause (roughly ages 45-55): Estrogen begins declining. Adding prednisone to a perimenopausal baseline accelerates trabecular bone loss at the spine. Resmetirom provides no known bone protection. If your rheumatologist or internist prescribes prednisone chronically, a dual-energy X-ray absorptiometry (DEXA) scan is appropriate.

Postmenopause: Postmenopausal women on chronic glucocorticoids have a fracture risk approximately 2-fold higher than age-matched non-users. The American College of Rheumatology 2022 GIOP guidelines recommend bisphosphonate therapy for postmenopausal women starting prednisone 7.5 mg/day or higher, regardless of baseline DEXA score.

What Resmetirom Does Not Do for Bone

Thyroid hormone receptor-beta agonists have complex effects on bone in animal models, with some evidence of increased bone turnover at supraphysiologic thyroid levels. Resmetirom at therapeutic doses, however, does not appear to cause thyrotoxicosis-level bone resorption; TSH was not meaningfully suppressed in MAESTRO-NASH participants. Still, resmetirom should not be assumed to be bone-neutral in the long term, and no specific bone density data from MAESTRO-NASH has been published.

Immunity and Infection Risk

Prednisone suppresses T-cell and macrophage function. Women with MASH-related liver fibrosis already have some degree of immune dysregulation at the hepatic level. Combining chronic corticosteroid use with advanced liver disease increases susceptibility to:

• Bacterial infections (pneumonia, urinary tract infections, skin infections)
• Reactivation of latent tuberculosis
• Fungal infections, particularly candidiasis

Resmetirom itself is not immunosuppressive. The infection risk comes from prednisone. Women with cirrhosis or near-cirrhotic fibrosis (F4, outside the resmetirom indication but adjacent to it) face disproportionate risk from any immunosuppression. Cirrhosis-associated immune dysfunction, including reduced complement activity and impaired Kupffer cell function, compounds glucocorticoid-mediated immune suppression.

Cardiovascular and Lipid Considerations

Resmetirom significantly lowers LDL cholesterol. In MAESTRO-NASH, LDL was reduced by approximately 16-19% versus placebo at week 52. Prednisone moves lipids in the opposite direction: chronic glucocorticoid use raises LDL, total cholesterol, and triglycerides. Women after menopause already experience an adverse shift in lipid profile; adding chronic prednisone intensifies that shift.

The net cardiovascular effect of using resmetirom alongside prednisone is probably attenuated benefit from resmetirom's lipid-lowering, not reversal. A lipid panel at baseline and at 3-month intervals is reasonable when both drugs are active.

Pregnancy, Lactation, and Contraception

This section is required reading if you are of reproductive age or planning pregnancy.

Resmetirom in Pregnancy

Resmetirom is contraindicated in pregnancy. The FDA prescribing information states that resmetirom caused embryo-fetal toxicity in animal studies at doses lower than the maximum recommended human dose. No adequate human data on resmetirom use in pregnant women exist. Because of its mechanism (liver-directed THR-β agonism), fetal thyroid development, which depends on thyroid hormone signaling, may be at risk.

You must use effective contraception while taking resmetirom. The FDA label instructs women of reproductive potential to use a highly effective contraceptive method during treatment and for at least 7 days after the final dose.

Prednisone in Pregnancy

Prednisone and prednisolone have been used in pregnancy for autoimmune conditions for decades. A 2014 meta-analysis found no significant increase in major birth defects with first-trimester prednisone use, though a modest signal for oral clefts at high doses has been noted in some studies. Prednisone crosses the placenta minimally because placental 11β-HSD2 converts most prednisolone back to prednisone, a less active form. Still, chronic high-dose use is associated with preterm birth, gestational diabetes, and adrenal suppression in the neonate.

Because resmetirom is contraindicated in pregnancy, the practical question of combining both drugs in a pregnant woman does not arise. If you become pregnant on resmetirom, stop resmetirom immediately and contact your hepatologist and OB-GYN.

Lactation

No lactation data for resmetirom exist. Given the potential for serious adverse effects in a nursing infant, breastfeeding is not recommended during resmetirom treatment.

Prednisone is present in breast milk at low concentrations. At maternal doses below 40 mg/day, infant exposure is estimated at less than 1% of the weight-adjusted maternal dose, which most breastfeeding guidelines consider compatible with nursing.

PCOS, Insulin Resistance, and the MASH Connection

PCOS is present in up to 70% of women with insulin resistance, and insulin resistance is the metabolic engine of MASH in many premenopausal women. Women with PCOS who develop MASH and then require prednisone for a co-existing autoimmune condition face a three-way metabolic challenge:

• Baseline insulin resistance from PCOS
• Active hepatic inflammation from MASH
• Glucocorticoid-induced worsening of insulin resistance from prednisone

Resmetirom has not been studied specifically in women with PCOS-associated MASH. The MAESTRO-NASH trial did not stratify by PCOS status. PCOS is associated with a 2- to 4-fold higher odds of NAFLD/MASH compared to BMI-matched controls without PCOS, so this gap in evidence affects a substantial proportion of women who could be candidates for resmetirom.

If you have PCOS and are on both resmetirom and prednisone, your glucose monitoring should be more frequent (every 1-2 weeks initially) and your insulin-sensitizing therapy (if you use metformin) should be reviewed against updated glucose readings.

Who This Combination Is Right For and Who Should Reconsider

Situations Where the Combination May Be Appropriate

• Women with biopsy-confirmed MASH (F2-F3 fibrosis) who also have a flaring autoimmune condition requiring short-term prednisone (less than 14 days at a low dose, under 10 mg/day)
• Women for whom there is no steroid-sparing alternative and whose MASH is actively progressing without resmetirom
• Women in the reproductive years with intact glucose regulation and normal baseline bone density, who can be monitored closely

Situations That Warrant a Pause or Alternative

• Women with existing steroid-induced diabetes or HbA1c already above 7.0%
• Postmenopausal women with a T-score below -2.0 at the spine or hip who are not already on bone-protective therapy
• Women on chronic high-dose prednisone (20 mg/day or more for more than 3 months) where the metabolic antagonism is likely to be sustained

The Steroid-Sparing Strategy

The best clinical solution for many women in this situation is to reduce prednisone exposure. Steroid-sparing agents such as methotrexate, azathioprine, mycophenolate, or biologic DMARDs are appropriate in autoimmune conditions that previously required chronic glucocorticoids. Requesting a rheumatology or allergy consultation to minimize prednisone dose is a reasonable step when resmetirom is newly started.

Drug Interaction Summary Table

| Parameter | Resmetirom | Prednisone | Combined Risk | |---|---|---|---| | Primary metabolism | CYP2C8, CYP3A4 | CYP3A4 (substrate) | Low PK interaction risk | | Transporter | OATP1B1/1B3 (uptake) | Not significant | No transporter conflict | | Glucose effect | Improves insulin sensitivity | Worsens insulin resistance | Additive metabolic harm | | Lipid effect | Lowers LDL 16-19% | Raises LDL and triglycerides | Attenuates resmetirom benefit | | Bone effect | Neutral (no data for protection) | Causes GIOP | Unprotected bone loss | | Liver fat | Reduces hepatic steatosis | Promotes hepatic lipid accumulation | Pharmacodynamic antagonism | | Pregnancy | Contraindicated | Caution, low-dose acceptable | Both require OB-GYN input |

Counseling Points for Your Appointment

When you speak with your hepatologist, internist, or rheumatologist about this combination, ask these specific questions:

1. "What is my current DEXA scan result, and do I need a bisphosphonate given my prednisone dose?"
2. "Should I be checking my glucose 2 hours after meals, not just fasting, while on prednisone?"
3. "Is there a steroid-sparing option for my autoimmune condition so I can reduce my prednisone dose?"
4. "Will you recheck my LFTs and lipid panel at my next visit to see whether resmetirom is still producing benefit?"
5. "Do I need to adjust my contraception? I understand resmetirom requires highly effective birth control."

As Dr. Elena Vasquez, MD, WomanRx medical reviewer, notes: "Women with MASH are rarely managing just one condition. The combination of resmetirom and prednisone is not automatically contraindicated, but it demands the kind of proactive monitoring that a busy clinic visit can easily miss. Glucose, lipids, and bone density should be on the checklist at every visit for any woman on both drugs."